ArticleFrontiers in medicine2018
Compositional Quality and Potential Gastrointestinal Behavior of Probiotic Products Commercialized in Italy.
Article in Frontiers in medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 35 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A Comprehensive Review and Meta-analysis on the Treatment of Acute Gastroenteritis in Children with a Bacillus clausii Preparation (EnterogerminaAdvances in therapy · 2025Pooled it
- Review
- Probiotics and the Human Microbiome: Classical Functions, Emerging Systemic Roles, and Future Therapeutic Frontiers.Biology · 2026Review
- Article
- Evaluating the Compositional Quality of Probiotics Containing Bacillus clausii in India.Advances in therapy · 2025Article
- Probiotic potential and safety assessment of bacteriocinogenicFrontiers in microbiology · 2025Article
- A Taguchi Approach for Optimization of Antimicrobial Effect of Whey Protein Based Edible Film Fermented byPolymers · 2024Article
- The Effect of Food Matrix Taken with Probiotics on the Survival of Commercial Probiotics in Simulation of Gastrointestinal Digestion.Foods (Basel, Switzerland) · 2024Article
- Chitosan-coated probiotic nanoparticles mitigate acrylamide-induced toxicity in the Drosophila model.Scientific reports · 2024Article
- Strain-Dependent Adhesion Variations ofMicroorganisms · 2024Article
- Sodium Deoxycholate-Propidium Monoazide Droplet Digital PCR for Rapid and Quantitative Detection of ViableMicroorganisms · 2024Article
- Unveiling the Probiotic Potential ofMicroorganisms · 2024Article
- Role of Probiotics in the Treatment and Prevention of Common Gastrointestinal Conditions in Children.Pediatric gastroenterology, hepatology & nutrition · 2024Review
- Screening, Identification and Physiological Characteristics ofFoods (Basel, Switzerland) · 2023Article
- Optimization, Probiotic Characteristics, and Rheological Properties of Exopolysaccharides fromMolecules (Basel, Switzerland) · 2023Article
- Gamma-Aminobutyric Acid-ProducingFoods (Basel, Switzerland) · 2023Article
- Analysis of the microbial content of probiotic products commercialized worldwide and survivability in conditions mimicking the human gut environment.Frontiers in microbiology · 2023Article
- In vitro assessment of probiotic attributes for strains contained in commercial formulations.Scientific reports · 2022Article
- Current Progress and Future Perspectives on the Use of Bacillus clausiiMicroorganisms · 2022Review
- Compositional Quality and Possible Gastrointestinal Performance of Marketed Probiotic Supplements.Probiotics and antimicrobial proteins · 2022Article
Corrections and comments
- Erratum issued
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent guidelines indicate that oral probiotics, living microorganisms able to confer a health benefit on the host, should be safe for human consumption, when administered in a sufficient amount, and resist acid and bile to exert their beneficial effects (e.g., metabolic, immunomodulatory, anti-inflammatory, competitive). This study evaluated quantitative and qualitative aspects and the viability in simulated gastric and intestinal juices of commercial probiotic formulations available in Italy. Plate counting and MALDI-TOF mass spectrometry were used to enumerate and identify the contained organisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.